The study is designed to demonstrate the efficacy of Vaxart’s oral COVID-19 vaccine candidate.
“We are very pleased to be one of the few companies selected for Operation Warp Speed and that ours is the only oral vaccine under evaluation. SARS-CoV-2, the coronavirus that causes COVID-19, is mainly transmitted by viral particles that enter the mucosa – nose, mouth or eyes – strongly suggesting that mucosal immunity could serve as the first line of defense. said Andrei Floroiu. , CEO of Vaxart Inc. “In addition, our vaccine is a stable room temperature tablet, a huge logistical advantage in large vaccination campaigns.”
The story continues